Tiziana Life Sciences PLC is a clinical-stage biotechnology company. The Company is focused on targeted drugs to treat diseases in oncology and immunology, with a focus on metastatic cancers. Its lead product candidates include Milciclib (TZLS-201) and Foralumab (TZLS-401). Its products also include Anti IK-6r (TZLS-501) and StemPrintER. The Company is focused on its lead compound, Milciclib, a molecule which blocks the action of specific enzymes called cyclin-dependent kinases (CDK) involved in cell division, as well as a number of other protein kinases. Milciclib has completed Phase IIa trials as a monotherapy for the treatment for thymic carcinoma and hepatocellular carcinoma (HCC). The Company's Foralumab is a fully human engineered anti-human cluster of differentiation 3 (CD3) antibody. Foralumab has completed Phase II trial and has potential application in a wide range of autoimmune and inflammatory diseases.